文献速递主动脉疾病慢性静脉疾病

腹主动脉瘤继发主动脉腔静脉瘘的治疗:系统综述

Treatment of Aortocaval Fistula Secondary to Abdominal Aortic Aneurysm: A Systematic Review.
PubMed 文献 · Ann Vasc Surg · 2022-12-07

该系统综述检索2000至2022年英文文献,纳入110项病例研究共196例患者(平均年龄66.2岁,男性96%),比较开放手术与腔内修复治疗腹主动脉瘤继发主动脉腔静脉瘘的早期和中期结局。开放手术占78%(153/196),两种方式技术成功率分别为99%(152/153)和100%(43/43),30天生存率分别为87.5%(126/144)和97.6%(42/43),中期生存率分别为86%(74/86)和95.2%(20/21),腔内修复后再干预率为35.7%(15/42)。

要点

  • 开放手术占78%(153/196),技术成功率99%(152/153),30天生存率87.5%(126/144),中期生存率86%(74/86)。
  • 腔内修复技术成功率100%(43/43),30天生存率97.6%(42/43),中期生存率95.2%(20/21)。
  • 腔内修复后内漏发生率为39.5%(19例),其中II型内漏最常见,发生率为32.5%(14/43)。

核心结论

  • 开放手术和腔内修复治疗腹主动脉瘤继发主动脉腔静脉瘘均与极佳的技术成功率和可接受的早期及中期生存结局相关。
  • 腔内修复患者的再干预仍是一个问题。

研究设计与样本

  • 系统综述,检索PubMed、SCOPUS和CENTRAL数据库中2000年至2022年发表的英文医学文献,遵循PRISMA 2020指南,研究方案注册于PROSPERO(CRD42022329058)。
  • 纳入报告开放手术或腔内修复后原发性主动脉腔静脉瘘结局的研究,采用ROBINS-I工具评估偏倚风险。
  • 共纳入110项病例研究,包含196例患者(平均年龄66.2岁,男性96%)。

主要发现

  • 开放手术修复应用于78%(153/196)的患者。
  • 开放手术与腔内修复的技术成功率分别为99%(152/153)和100%(43/43)。
  • 开放手术与腔内修复的30天生存率分别为87.5%(126/144)和97.6%(42/43)。
  • 开放手术与腔内修复的中期生存率分别为86%(74/86)和95.2%(20/21),中位随访14个月(范围1-54个月)。
  • 腔内修复病例中报告内漏19例(39.5%),其中II型内漏最常见,发生率为32.5%(14/43);开放手术与腔内修复的再干预率分别为2.5%(4/151)和35.7%(15/42)。

局限性

  • 关于该罕见病治疗发表的病例研究很少。
  • 几乎所有有创操作均在男性中实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Aortocaval fistula (ACF) secondary to an abdominal aortic aneurysm is a rare complication, inadvertently caused by a rupture into the inferior vena cava. Different treatment modalities have been applied toward the repair of such lesions, including open surgical and endovascular repair. The aim of this study was to report on ACF treatment and to analyze its early and mid-term outcomes. METHODS: A systematic search of the English medical literature published between 2000 and 2022 was undertaken, using PubMed, SCOPUS, and CENTRAL databases as per the Preferred Reporting Items for Systematic Reviews and Meta-Analysis 2020 guidelines. A study protocol was registered in PROSPERO (CRD42022329058). Studies reporting on primary ACF outcomes following open surgical or endovascular repair were included. The ROBINS-I tool was applied for risk of bias assessment. Outcomes included technical success, 30-day and mid-term survival, endoleak following endovascular repair, and reintervention rates. RESULTS: In total, 110 case studies, incorporating 196 patients (mean age; 66.2 years, males 96%) were included. Open surgical repair was applied in 78% (153/196). From the available data, technical success rate for each modality was 99% (152/153) and 100% (43/43), respectively. Open and endovascular repair demonstrated 87.5% (126/144) and 97.6% (42/43) 30-day survival, respectively, while mid-term survival was 86% (74/86) and 95.2% (20/21), respectively (medial follow-up: 14 months [1-54 months]). Endoleaks were reported in 19 endovascular cases (39.5%). Type II endoleak was the most frequent with a rate at 32.5% (14/43). Reintervention rates were 2.5% (4/151) and 35.7% (15/42) for open and endovascular repair, respectively. CONCLUSIONS: Only few case studies were published on the treatment of this rare condition, while almost all invasive procedures were performed in males. Management of ACF repair with both open and endovascular approach was associated with excellent technical success rate and acceptable early and mid-term survival outcomes. Reintervention remained an issue for patients who were managed endovascularly.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Dakis K, Nana P, Kouvelos G, et al. Treatment of Aortocaval Fistula Secondary to Abdominal Aortic Aneurysm: A Systematic Review. Ann Vasc Surg. 2022. PMID: 36496094. doi:10.1016/j.avsg.2022.11.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。